885618-33-7

Basic information

• Product Name: 4-(4,4,5,5-TETRAMETHYL-[1,3,2]DIOXABOROLAN-2-YL)-1H-INDAZOLE
• Synonyms: 1H-Indazole, 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-;1H-Indazol-4-ylboronic Acid Pinacol Ester;1H-Indazole-4-boronic acid pinacol ester;Indazole-4-boronic acid p...;2-dioxaborolan-2-yl)-1H-indazole;4-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1h-indazole;3-hydroxy-2,3-dimethylbutan-2-yl hydrogen 1H-indazol-4-ylboronate;1H-indazol-4-boronic acid pinacol ester
• CAS NO: 885618-33-7
• Molecular Formula: C₁₃H₁₇BN₂O₂
• Molecular Weight: 244.1
• Product Categories: Indazoles
• Mol File: 885618-33-7.mol
• Article Data: 16

Chemical Properties

• Melting Point: 139-142℃
• Boiling Point: 404.123 °C at 760 mmHg
• Flash Point: 198.207 °C
• Appearance: /
• Density: 1.154 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.564
• Storage Temp.: Refrigerated.
• CAS DataBase Reference: 4-(4,4,5,5-TETRAMETHYL-[1,3,2]DIOXABOROLAN-2-YL)-1H-INDAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4,4,5,5-TETRAMETHYL-[1,3,2]DIOXABOROLAN-2-YL)-1H-INDAZOLE(885618-33-7)
• EPA Substance Registry System: 4-(4,4,5,5-TETRAMETHYL-[1,3,2]DIOXABOROLAN-2-YL)-1H-INDAZOLE(885618-33-7)

Safety Data

• Hazardous Substances Data: 885618-33-7(Hazardous Substances Data)

Usage

General Description

4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-indazole is a chemical compound with potential applications in the fields of chemistry and pharmaceuticals. It contains a dioxaborolane group, which is known for its ability to form stable complexes with a wide range of organic compounds. The presence of the indazole ring also makes this compound of interest for its potential biological activity, as indazoles are known to exhibit a variety of pharmacological properties. The tetramethyl substitution on the dioxaborolane group contributes to the stability and reactivity of the compound, making it a valuable building block for the synthesis of novel molecules with potential medicinal applications. This chemical may have potential as a drug target, or as a starting material for the development of new pharmaceutical compounds.

InChI:InChI=1/C13H17BN2O2/c1-12(2)13(3,4)18-14(17-12)10-6-5-7-11-9(10)8-15-16-11/h5-8H,1-4H3,(H,15,16)

Upstream product

• 885698-70-4 1-(4-bromo-1H-indazol-1-yl)ethanone 
• 55289-36-6 3-bromo-2-methylaniline 
• 73183-34-3 bis(pinacol)diborane 
• 186407-74-9 4-bromoindazole 

Downstream Products

• 957474-75-8 C₂₃H₂₅N₃OSSi 
• 1186421-53-3 3-(3-(1H-indazol-4-yl)-2-(pyridin-4-yl)pyrazolo[1,5-a]pyrimidin-7-yl)-n,n-dimethylbenzenesulfonamide 
• 1542268-06-3 (1r,4r)-4-((4-(2H-indazol-4-yl)-6-morpholino-1,3,5-triazine-2-yl)oxy)-N,N-dimethycyclohexanecarboxamide hydrochloride 
• 1542268-07-4 C₂₈H₃₇N₇O₄ 
• 1391925-69-1 3-((4-(1H-indazol-4-yl)-6-morpholino-1,3,5-triazin-2-yl)amino)benzoic acid 
• 1391925-55-5 3-((4-(1H-indazol-4-yl)-6-morpholino-1,3,5-triazin-2-yl)amino)-N,N-dimethylbenzamide 
• 1391926-45-6 C₂₇H₃₀N₆O₃ 
• 1391926-39-8 C₂₉H₃₃N₇O₄ 
• 1391926-38-7 C₃₁H₃₀N₆O₃S 
• 1391926-60-5 C₃₁H₃₀N₆O₅S 
• 1391926-36-5 C₂₈H₃₁N₇O₄ 
• 1391926-35-4 4-(4-(benzylsulfonyl)-6-(2-(tetrahydro-2H-pyran-2-yl)-2H-indazol-4-yl)-1,3,5-triazin-2-yl)morpholine 
• 1391926-34-3 4-(4-(benzylthio)-6-(2-(tetrahydro-2H-pyran-2-yl)-2H-indazol-4-yl)-1,3,5-triazin-2-yl)morpholine 
• 1146955-35-2 2-(tetrahydro-2H-pyran-2-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2H-indazole 

Relevant articles and documents

PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH ZINC BINDING MOIETY

PROBLEM TO BE SOLVED: To provide phosphoinositide 3-kinase inhibitors with a zinc binding moiety. SOLUTION: There is provided a compound represented by formula (I) in the figure. (X is S, O or the like; Y is CH, N or the like; G1 is optionally substituted N or the like; R1 and R2 are each independently H or the like; C is a substituted heterocycle or the like; B is a linear alkyl or the like; Ra and Rb together with the nitrogen atom coupled to them are morpholino or the like; G2 is an indazole ring or the like; q, r and s are independently from 0 to 1, provided that at least one of them is 1; t is from 0 to 1; n is from 0 to 4; and p is from 0 to 2.) COPYRIGHT: (C)2016,JPOandINPIT

Linear propargylic alcohol functionality attached to the indazole-7-carboxamide as a JAK1-specific linear probe group

Selective inhibition of JAK1 has recently been proposed as an appropriate therapeutic rationale for the treatment of inflammatory diseases such as rheumatoid arthritis (RA) In this study, through pairwise comparison and 3D alignment of the JAK isozyme structures bound to the same inhibitor molecule, we reasoned that an alkynol functionality would serve as an isozyme-specific probe group, which would enable the resulting inhibitor to differentiate the ATP-binding site of JAK1 from those of other isozymes The 3-alkynolyl-5- (4′-indazolyl)indazole-7-carboxamide derivatives were thus prepared, and in vitro evaluation of their inhibitory activity against the JAK isozymes revealed that the propargyl alcohol functionality endowed the 5-(4′-indazolyl)indazole-7-carboxamide scaffold with JAK1 selectivity over other JAK isozymes, particularly JAK2

TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE

Tricyclic PI3k inhibitor compounds of Formula I with anti-cancer activity, anti- inflammatory activity, or immunoregulatory properties, and more specifically with PI3 kinase modulating or inhibitory activity are described. Methods are described for using the tricyclic PI3K inhibitor compounds of Formula I for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, organisms, or associated pathological conditions. Formula I compounds include stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof. The dashed lines indicate an optional double bond, and at least one dashed line is a double bond. The substituents are as described.